Bipolar Disorder (2018) |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Bipolar Disorder or Schizophrenia |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Depressed Affect (Nagel 2018) |
2.02 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 HORMAD2 |
Intelligence (Savage-Jansen 2018) |
0.80 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 PAM RAB5B |
Neuroticism (Nagel 2018) |
2.13 |
4 |
0 |
0.0 |
0.99 |
1.5e-04 |
AL133458.1 HORMAD2 RNASET2 TIMP4 |
Schizophrenia (2018) |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
U91328.19 |
Schizophrenia vs Biploar Disorder |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
VPS29 |
Worry (Nagel 2018) |
1.78 |
5 |
0 |
0.0 |
0.67 |
2.2e-01 |
HORMAD2 PAM RNASET2 TIMP4 U91328.19 |
Crohns Disease (2017) |
5.00 |
10 |
3 |
6.7 |
0.11 |
7.2e-01 |
AL133458.1 BCL2L15 DCLRE1B FADS2 GIGYF1 GPR31 HIPK1 HORMAD2 PTPN22 RNASET2 |
Irritable Bowel Disease (IBD) |
3.25 |
4 |
2 |
4.4 |
0.90 |
6.5e-03 |
AL133458.1 HECTD4 HORMAD2 RNASET2 |
Reaction Time |
2.47 |
4 |
2 |
4.4 |
0.75 |
8.4e-02 |
ALDH2 HECTD4 RAB5B RP3-462E2.3 |
Verbal and Numeric Reasoning (VNR) |
1.18 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 PAM RAB5B |
Breast Cancer |
1.40 |
4 |
2 |
4.4 |
-0.98 |
3.0e-03 |
BCL2L15 DCLRE1B PHTF1 PTPN22 |
Coronary Artery Disease (CAD) |
2.80 |
3 |
0 |
0.0 |
0.95 |
5.3e-02 |
HECTD4 UHRF1BP1 VPS29 |
Crohns Disease (2012) |
4.28 |
5 |
2 |
4.4 |
0.20 |
6.4e-01 |
AL133458.1 FADS2 HIPK1 HORMAD2 RNASET2 |
Fasting Glucose |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
HbA1C |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A |
HDL Cholesterol |
1.99 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS2 UHRF1BP1 |
LDL Cholesterol |
2.73 |
3 |
2 |
4.4 |
0.86 |
6.2e-02 |
ALDH2 FADS2 HECTD4 |
Lupus |
3.48 |
4 |
1 |
2.2 |
0.78 |
1.2e-01 |
DCLRE1B HECTD4 NAB1 SGK223 |
Neuroticism (2016) |
1.63 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SGK223 |
Primary Biliary Cirrhosis |
3.15 |
3 |
0 |
0.0 |
0.86 |
1.4e-01 |
HECTD4 MMEL1 NAB1 |
Rheumatoid Arthritis |
12.81 |
13 |
8 |
17.8 |
0.94 |
2.3e-07 |
BCL2L15 DCLRE1B FAM208B GPR31 HECTD4 HIPK1 MMEL1 NAB1 OLFML3 PAM PHTF1 PTPN22 RASGRP1 |
Schizophrenia (2014) |
1.05 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIGYF1 SGK223 |
Triglycerides |
1.90 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS2 |
Blood Eosinophil Count |
12.02 |
17 |
13 |
28.9 |
0.72 |
3.0e-04 |
ADAM1A ALDH2 BACH2 EFCAB13 FADS2 FAM208B GIGYF1 GPR31 HECTD4 NAB1 NPEPPS RAB5B RASGRP1 RP3-462E2.3 SLC1A2 TIMP4 VPS29 |
Blood Platelet Count |
6.36 |
15 |
10 |
22.2 |
0.28 |
2.2e-01 |
ADAM1A C1QTNF6 C9orf156 CAPZB FADS2 FOXE1 HECTD4 NAB1 PAM RP3-462E2.3 TIMP4 TMOD1 TSTD2 UHRF1BP1 VPS29 |
Blood Red Count |
2.96 |
15 |
11 |
24.4 |
0.59 |
1.0e-02 |
ADAM1A ALDH2 ANP32B BACH2 C9orf156 FADS2 GIGYF1 HECTD4 NAB1 NPEPPS PAM RAB5B RP3-462E2.3 TG VPS29 |
Blood White Count |
5.85 |
18 |
15 |
33.3 |
0.37 |
8.3e-02 |
ADAM1A ALDH2 BACH2 BCL2L15 DCLRE1B FADS2 HECTD4 HORMAD2 HSPB9 OLFML3 PAM PHTF1 PTPN22 RAB2A RNASET2 RP3-462E2.3 TIMP4 VPS29 |
Heel T-Score |
0.84 |
8 |
4 |
8.9 |
0.09 |
8.3e-01 |
ANP32B BACH2 CAPZB DCLRE1B FADS2 NAB1 PUSL1 RAB5B |
BMI |
1.33 |
4 |
2 |
4.4 |
-0.54 |
3.5e-01 |
HECTD4 RAB5B UHRF1BP1 VPS29 |
Height |
1.21 |
20 |
16 |
35.6 |
-0.51 |
7.0e-03 |
ADAM1A ALDH2 ANP32B C9orf156 CAPZB COL15A1 EFCAB13 FADS2 HECTD4 HORMAD2 HSPB9 NAB1 NCBP1 NPEPPS NR3C2 PAM PUSL1 RP3-462E2.3 SLC1A2 UHRF1BP1 |
Waist Hip Ratio (WHR) |
1.26 |
6 |
4 |
8.9 |
0.65 |
1.6e-01 |
ADAM1A BACH2 HECTD4 PAM TIMP4 UHRF1BP1 |
Systolic Blood Pressure |
2.42 |
7 |
7 |
15.6 |
0.87 |
2.3e-03 |
ADAM1A ALDH2 HECTD4 NAB1 PUSL1 RP3-462E2.3 VPS29 |
Smoking Status |
1.22 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAM1A PTPN22 RAB5B |
Allergy or Eczema |
2.23 |
5 |
4 |
8.9 |
-0.38 |
4.5e-01 |
ADAM1A BACH2 COL15A1 HECTD4 RAB5B |
Cardiovascular Disease |
2.20 |
6 |
3 |
6.7 |
0.82 |
1.2e-02 |
ADAM1A ALDH2 HECTD4 RAB5B UHRF1BP1 VPS29 |
Hypothyroidism (self reported) |
40.36 |
48 |
44 |
97.8 |
0.99 |
2.5e-57 |
ADAM1A AL133458.1 ALDH16A1 ALDH2 ANP32B BACH2 BCL2L15 C1QTNF6 C9orf156 CAPZB DCLRE1B EFCAB13 FADS2 FAM208B FEM1A FOXE1 GIGYF1 GPR31 HECTD4 HIPK1 HORMAD2 HSPB9 IL15RA MMEL1 NAB1 NCBP1 NPEPPS NR3C2 OLFML3 PAM PHTF1 PTPN22 PUSL1 RAB2A RAB5B RASGRP1 RNASET2 RP3-462E2.3 SGK223 SLC1A2 TG TICAM1 TIMP4 TMOD1 TSTD2 UHRF1BP1 VAV3 VPS29 |
Respiratory disease |
2.27 |
4 |
3 |
6.7 |
-0.98 |
1.7e-02 |
BACH2 FADS2 FAM208B RAB5B |
Type 2 Diabetes (T2D) (2018) |
1.70 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A PAM |
Lung FEV1/FVC ratio |
1.16 |
5 |
3 |
6.7 |
-0.65 |
2.4e-01 |
ANP32B C9orf156 NCBP1 RAB5B SLC1A2 |
Lung FVC |
1.16 |
7 |
1 |
2.2 |
0.13 |
7.7e-01 |
ALDH2 HECTD4 HORMAD2 HSPB9 PAM RAB5B RP3-462E2.3 |
Neuroticism |
1.80 |
4 |
0 |
0.0 |
0.43 |
5.7e-01 |
AL133458.1 C9orf156 HORMAD2 TIMP4 |
Chronotype (morning person) |
1.45 |
4 |
0 |
0.0 |
0.48 |
4.1e-01 |
ALDH2 HECTD4 HORMAD2 TIMP4 |
Hair Pigment |
0.54 |
9 |
7 |
15.6 |
0.33 |
2.2e-01 |
ALDH2 ANP32B C9orf156 EFCAB13 FADS2 GIGYF1 HECTD4 RP3-462E2.3 TSTD2 |
Tanning |
0.30 |
3 |
0 |
0.0 |
0.98 |
2.2e-02 |
ALDH2 HECTD4 RP3-462E2.3 |
Number of treatments/medications taken |
3.73 |
9 |
2 |
4.4 |
0.98 |
4.6e-09 |
ADAM1A AL133458.1 BCL2L15 DCLRE1B FADS2 FAM208B HECTD4 PTPN22 RNASET2 |
Sensitivity / hurt feelings |
1.59 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SGK223 |
Frequency of depressed mood in last 2 weeks |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HSPB9 |
Other serious medical condition/disability diagnosed by doctor |
2.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCLRE1B |
Systolic blood pressure, automated reading |
1.71 |
5 |
4 |
8.9 |
0.19 |
6.8e-01 |
ALDH2 HECTD4 NAB1 PUSL1 SGK223 |
Vitamin and mineral supplements |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
U91328.19 |
Impedance of leg (right) |
1.16 |
4 |
3 |
6.7 |
0.57 |
4.3e-01 |
PAM RAB5B SGK223 UHRF1BP1 |
Leg fat-free mass (left) |
1.86 |
10 |
8 |
17.8 |
-0.45 |
1.6e-01 |
ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Trunk fat percentage |
1.38 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
U91328.19 UHRF1BP1 |
Fed-up feelings |
2.14 |
4 |
1 |
2.2 |
-0.78 |
6.6e-02 |
ALDH2 HECTD4 HORMAD2 SGK223 |
Relative age voice broke |
0.97 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A |
Taking other prescription medications |
6.41 |
11 |
7 |
15.6 |
0.98 |
7.8e-10 |
ADAM1A AL133458.1 BCL2L15 DCLRE1B FAM208B HECTD4 HIPK1 HSPB9 PTPN22 RNASET2 UHRF1BP1 |
Heel bone mineral density (BMD) T-score, automated (left) |
1.74 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS2 SGK223 U91328.19 |
Serious illness, injury or assault to yourself |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTPN22 |
High blood pressure |
2.05 |
5 |
3 |
6.7 |
0.28 |
5.5e-01 |
ADAM1A ALDH2 HECTD4 RAB5B SGK223 |
Hayfever, allergic rhinitis or eczema |
2.41 |
6 |
3 |
6.7 |
-0.36 |
4.8e-01 |
ADAM1A BACH2 COL15A1 HECTD4 RAB5B U91328.19 |
Medication: Atenolol |
2.46 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ALDH2 HECTD4 |
Sitting height |
1.00 |
8 |
4 |
8.9 |
-0.32 |
4.1e-01 |
ANP32B C9orf156 CAPZB COL15A1 FADS2 HORMAD2 U91328.19 UHRF1BP1 |
Body mass index (BMI) |
1.80 |
6 |
4 |
8.9 |
-0.38 |
4.6e-01 |
HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Impedance of leg (left) |
1.09 |
4 |
3 |
6.7 |
0.56 |
4.4e-01 |
PAM RAB5B SGK223 UHRF1BP1 |
Leg predicted mass (left) |
1.86 |
10 |
7 |
15.6 |
-0.45 |
1.7e-01 |
ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Trunk fat mass |
1.70 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ANP32B U91328.19 UHRF1BP1 |
Waist circumference |
1.35 |
5 |
2 |
4.4 |
-0.51 |
3.9e-01 |
ALDH2 HECTD4 RAB5B U91328.19 UHRF1BP1 |
Past tobacco smoking |
1.88 |
5 |
0 |
0.0 |
0.16 |
7.6e-01 |
ADAM1A ALDH2 HECTD4 PTPN22 RAB5B |
Nervous feelings |
1.62 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
HORMAD2 SGK223 U91328.19 |
Hearing difficulty/problems with background noise |
1.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
U91328.19 |
Forced vital capacity (FVC) |
0.89 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
HORMAD2 RAB5B |
Heel bone mineral density (BMD) T-score, automated (right) |
1.74 |
4 |
1 |
2.2 |
-0.39 |
6.1e-01 |
CAPZB FADS2 SGK223 U91328.19 |
Ever unenthusiastic/disinterested for a whole week |
1.71 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TIMP4 |
Qualifications: None of the above |
1.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RAB5B |
Allergy |
1.97 |
6 |
3 |
6.7 |
0.13 |
8.1e-01 |
ADAM1A BACH2 COL15A1 FADS2 RAB5B U91328.19 |
Diabetes (self-reported) |
1.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTPN22 |
Hayfever/allergic rhinitis (self-reported) |
1.96 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB5B U91328.19 |
Medication: Ramipril |
1.50 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A |
Medication: Simvastatin |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Fluid intelligence score |
1.05 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 RAB5B |
Illnesses of siblings |
1.26 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A HECTD4 |
Neuroticism score |
2.38 |
4 |
1 |
2.2 |
0.53 |
4.7e-01 |
HORMAD2 SGK223 TIMP4 U91328.19 |
Weight |
2.07 |
9 |
5 |
11.1 |
-0.53 |
1.1e-01 |
ALDH2 ANP32B HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Impedance of arm (right) |
1.39 |
7 |
4 |
8.9 |
0.55 |
2.0e-01 |
ADAM1A HECTD4 NR3C2 RAB5B SGK223 UHRF1BP1 VPS29 |
Arm fat percentage (right) |
1.29 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
SGK223 U91328.19 UHRF1BP1 |
Trunk fat-free mass |
1.71 |
11 |
7 |
15.6 |
-0.72 |
5.4e-03 |
ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 U91328.19 UHRF1BP1 VPS29 |
Hip circumference |
2.24 |
9 |
5 |
11.1 |
-0.40 |
2.3e-01 |
ALDH2 EFCAB13 HECTD4 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Father's age at death |
1.62 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Worrier / anxious feelings |
1.82 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PAM SGK223 |
Frequency of tiredness / lethargy in last 2 weeks |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Number of live births |
1.79 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 HORMAD2 |
Forced expiratory volume in 1-second (FEV1) |
1.10 |
4 |
2 |
4.4 |
-0.59 |
4.1e-01 |
HORMAD2 RAB5B SGK223 U91328.19 |
Pulse rate |
1.88 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS2 GIGYF1 |
Qualifications: A levels/AS levels or equivalent |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB5B |
Mouth/teeth dental problems: Dentures |
1.35 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SGK223 U91328.19 |
Asthma |
1.99 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
BACH2 FADS2 RAB5B |
Medication: Ibuprofen (e.g. Nurofen) |
1.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Forced expiratory volume in 1-second (FEV1), Best measure |
0.95 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
HORMAD2 RAB5B SGK223 |
Pulse wave Arterial Stiffness index |
1.70 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAM1A |
Impedance of arm (left) |
1.41 |
8 |
4 |
8.9 |
0.66 |
5.5e-02 |
ADAM1A HECTD4 NR3C2 RAB5B RP3-462E2.3 SGK223 UHRF1BP1 VPS29 |
Arm fat mass (right) |
1.73 |
5 |
4 |
8.9 |
-0.41 |
4.9e-01 |
HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 |
Trunk predicted mass |
1.73 |
12 |
7 |
15.6 |
-0.73 |
3.2e-03 |
ADAM1A ALDH2 ANP32B COL15A1 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 U91328.19 UHRF1BP1 VPS29 |
Standing height |
1.24 |
14 |
9 |
20.0 |
-0.29 |
2.1e-01 |
ALDH2 ANP32B C9orf156 CAPZB COL15A1 EFCAB13 FADS2 HECTD4 HORMAD2 HSPB9 NAB1 NPEPPS SGK223 U91328.19 |
Exposure to tobacco smoke at home |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UHRF1BP1 |
Breastfed as a baby |
1.45 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PUSL1 |
Tense / 'highly strung' |
1.65 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SGK223 TIMP4 |
Hair/balding pattern: Pattern 4 |
0.81 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Birth weight of first child |
2.74 |
6 |
1 |
2.2 |
-0.72 |
4.3e-02 |
ADAM1A ALDH2 HECTD4 RAB2A RAB5B RP3-462E2.3 |
Peak expiratory flow (PEF) |
1.18 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
PUSL1 SGK223 |
Medication: Paracetamol |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB5B |
Headache pain in last month |
1.97 |
4 |
1 |
2.2 |
-0.92 |
2.7e-02 |
ALDH2 HECTD4 RAB5B U91328.19 |
Medication for cholesterol, blood pressure or diabetes |
1.55 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADAM1A |
Gout (self-reported) |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Hypothyroidism/myxoedema (self-reported) |
34.42 |
50 |
46 |
102.2 |
1.00 |
2.3e-67 |
ADAM1A AL133458.1 ALDH16A1 ALDH2 ANP32B BACH2 BCL2L15 C1QTNF6 C9orf156 CAPZB COL15A1 DCLRE1B EFCAB13 FADS2 FAM208B FEM1A FOXE1 GIGYF1 GPR31 HECTD4 HIPK1 HORMAD2 HSPB9 IL15RA MMEL1 NAB1 NCBP1 NPEPPS NR3C2 OLFML3 PAM PHTF1 PTPN22 PUSL1 RAB2A RAB5B RASGRP1 RNASET2 RP3-462E2.3 SGK223 SLC1A2 TG TICAM1 TIMP4 TMOD1 TSTD2 U91328.19 UHRF1BP1 VAV3 VPS29 |
Medication: Ventolin 100micrograms inhaler |
1.08 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
BACH2 RAB5B |
Birth weight |
2.57 |
6 |
2 |
4.4 |
-0.97 |
2.6e-04 |
ADAM1A ALDH2 DCLRE1B HECTD4 HORMAD2 VPS29 |
High blood pressure (siblings) |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Forced vital capacity (FVC), Best measure |
0.73 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
HORMAD2 RAB5B |
Body fat percentage |
1.44 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
U91328.19 UHRF1BP1 |
Leg fat percentage (right) |
1.69 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
SGK223 U91328.19 UHRF1BP1 |
Arm fat-free mass (right) |
1.94 |
11 |
8 |
17.8 |
-0.69 |
1.4e-02 |
ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Comparative body size at age 10 |
1.24 |
4 |
2 |
4.4 |
-0.59 |
4.1e-01 |
HORMAD2 SGK223 U91328.19 UHRF1BP1 |
Worry too long after embarrassment |
2.00 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SGK223 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.64 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
TIMP4 U91328.19 |
Wheeze or whistling in the chest in last year |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Age at first live birth |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB5B |
Pulse wave peak to peak time |
1.69 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADAM1A |
Qualifications: College or University degree |
1.00 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PAM RAB5B U91328.19 |
Emphysema/chronic bronchitis |
1.68 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Medication for pain relief, constipation, heartburn |
1.70 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
UHRF1BP1 |
Medication: Blood pressure |
1.72 |
3 |
1 |
2.2 |
0.88 |
1.2e-01 |
ADAM1A ALDH2 HECTD4 |
Medication: Omeprazole |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UHRF1BP1 |
Mean time to correctly identify matches |
2.25 |
3 |
2 |
4.4 |
0.98 |
3.2e-03 |
ALDH2 HECTD4 RP3-462E2.3 |
Whole body fat mass |
1.77 |
8 |
2 |
4.4 |
-0.36 |
3.9e-01 |
ALDH2 ANP32B HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Leg fat mass (right) |
1.97 |
7 |
3 |
6.7 |
-0.47 |
2.4e-01 |
ALDH2 HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Arm predicted mass (right) |
1.98 |
11 |
8 |
17.8 |
-0.68 |
1.5e-02 |
ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Pulse rate, automated reading |
2.48 |
6 |
3 |
6.7 |
-0.51 |
3.0e-01 |
FADS2 GIGYF1 NAB1 RAB5B UHRF1BP1 VPS29 |
Alcohol intake frequency. |
0.97 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NPEPPS RAB5B |
Comparative height size at age 10 |
1.63 |
7 |
4 |
8.9 |
-0.95 |
1.4e-07 |
ALDH2 ANP32B C9orf156 CAPZB HECTD4 HORMAD2 NR3C2 |
Suffer from 'nerves' |
1.73 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Overall health rating |
1.59 |
4 |
0 |
0.0 |
0.46 |
5.4e-01 |
BCL2L15 PTPN22 SGK223 UHRF1BP1 |
Qualifications: NVQ or HND or HNC or equivalent |
1.49 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 |
Supplements: Vitamin C |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
U91328.19 |
Hypertension (Self-reported) |
1.85 |
5 |
3 |
6.7 |
0.23 |
6.2e-01 |
ADAM1A ALDH2 HECTD4 RAB5B SGK223 |
Illnesses of father: Heart disease |
1.63 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Smoking status: Previous |
1.91 |
3 |
0 |
0.0 |
0.74 |
1.5e-01 |
ALDH2 HECTD4 RAB5B |
Whole body fat-free mass |
1.82 |
13 |
6 |
13.3 |
-0.57 |
3.2e-02 |
ADAM1A ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Leg fat-free mass (right) |
1.85 |
9 |
8 |
17.8 |
-0.43 |
2.2e-01 |
ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Arm fat percentage (left) |
1.32 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
SGK223 U91328.19 UHRF1BP1 |
Mood swings |
1.66 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
HORMAD2 SGK223 |
Loneliness, isolation |
2.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RNASET2 |
Long-standing illness, disability or infirmity |
3.88 |
7 |
2 |
4.4 |
0.99 |
2.7e-08 |
AL133458.1 BCL2L15 DCLRE1B FAM208B PTPN22 RNASET2 UHRF1BP1 |
Diabetes diagnosed by doctor |
2.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTPN22 |
Friendships satisfaction |
1.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
VPS29 |
Mouth/teeth dental problems: Mouth ulcers |
2.14 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FEM1A PAM |
Medication for cholesterol |
2.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Mineral and other dietary supplements |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Asthma (self-reported) |
2.10 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
BACH2 FADS2 RAB5B |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
0.99 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RAB5B U91328.19 |
Whole body water mass |
1.83 |
13 |
6 |
13.3 |
-0.58 |
3.0e-02 |
ADAM1A ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Leg predicted mass (right) |
1.85 |
9 |
8 |
17.8 |
-0.43 |
2.2e-01 |
ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Arm fat mass (left) |
1.71 |
5 |
4 |
8.9 |
-0.39 |
5.1e-01 |
HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 |
Number of self-reported non-cancer illnesses |
3.54 |
6 |
1 |
2.2 |
0.98 |
1.5e-05 |
AL133458.1 ALDH2 FAM208B HECTD4 RNASET2 UHRF1BP1 |
Average weekly champagne plus white wine intake |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Miserableness |
2.08 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
HORMAD2 SGK223 |
Guilty feelings |
1.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Medication: Blood pressure |
2.04 |
3 |
2 |
4.4 |
0.76 |
1.4e-01 |
ALDH2 HECTD4 SGK223 |
Supplements: Fish oil (including cod liver oil) |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
High cholesterol (Self-reported) |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Medication: Bendroflumethiazide |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Medication: Lisinopril |
1.64 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 |
Ever smoked |
1.69 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
HECTD4 PTPN22 |
Basal metabolic rate |
1.95 |
13 |
7 |
15.6 |
-0.55 |
4.2e-02 |
ADAM1A ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Leg fat percentage (left) |
1.72 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
SGK223 U91328.19 UHRF1BP1 |
Arm fat-free mass (left) |
2.00 |
11 |
9 |
20.0 |
-0.70 |
7.2e-03 |
ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |
Average weekly beer plus cider intake |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SGK223 |
Irritability |
1.67 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS2 SGK223 |
Age started oral contraceptive pill |
1.81 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB5B RNASET2 |
Diastolic blood pressure, automated reading |
3.27 |
7 |
7 |
15.6 |
0.71 |
2.1e-02 |
ADAM1A ALDH2 GIGYF1 HECTD4 RP3-462E2.3 SGK223 VPS29 |
Unable to work because of sickness or disability |
1.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UHRF1BP1 |
Commuting to job workplace: Cycle |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UHRF1BP1 |
Myopia |
1.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Vascular/heart problems diagnosed by doctor |
2.08 |
5 |
4 |
8.9 |
-0.74 |
5.5e-02 |
ADAM1A ALDH2 HECTD4 SGK223 VPS29 |
Pain experienced in last month |
1.35 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ALDH2 HECTD4 RAB5B |
Impedance of whole body |
1.26 |
6 |
4 |
8.9 |
0.72 |
1.1e-01 |
ADAM1A HECTD4 RAB5B SGK223 UHRF1BP1 VPS29 |
Leg fat mass (left) |
2.00 |
6 |
3 |
6.7 |
-0.45 |
3.1e-01 |
HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29 |
Arm predicted mass (left) |
2.03 |
11 |
8 |
17.8 |
-0.70 |
8.1e-03 |
ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29 |